All In Biotech

Drug Trial Radar · NCT02414139

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

A Phase II, Multicenter Study of Oral MET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Last checked: Nov 19, 2026Latest source record: Mar 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

373

Actual

Start

Jun 11, 2015

Primary completion

Apr 12, 2023

Study completion May 16, 2023

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 10, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study to evaluate the efficacy and safety of capmatinib as a single-agent treatment for subjects with advanced/metastatic (stage IIIB or IV) non-small cell lung cancer (NSCLC) who had wild-type epidermal growth factor receptor (EGFR wt) (for exon 19 deletions and exon 21 L858R substitution mutations), anaplastic lymphoma kinase (ALK)-negative rearrangement, and mesenchymal epithelial transition (MET) mutations leading to exon 14 deletion (referred to as MET mutation hereafter) and/or MET amplification.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • CapmatinibDrug

    Capmatinib was administered orally, at a dose of 400 mg on a continuous twice daily dosing schedule. Capmatinib was administered to participants in Cohorts 1a, 1b, 2, 3, 4, 5a and 5b in a fasted state. For Cohorts 6.1. 6.2 and 7, capmatinib was administered either with or without food.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) by Blinded Independent Review Committee (BIRC) AssessmentTime frame: Up to approximately 5 years

Locations

95 sites in 20 countries. Site status is shown where the registry gives one.

  • Pacific Shores Medical Group SC

    Long Beach, California

  • University Of California Los Angeles Dept of Onc

    Los Angeles, California

  • University of California Irvine Medical Center Chao Family Chao Family Comp Cancer Center

    Orange, California

  • H Lee Moffitt Cancer Center and Research Institute .

    Tampa, Florida

  • University of Iowa Hospitals and Clinics SC-3

    Iowa City, Iowa

  • Massachusetts General Hospital MGH Cancer Center

    Boston, Massachusetts

  • VA Ann Arbor Health System VA Ann Arbor Health System

    Ann Arbor, Michigan

  • Mayo Clinic Rochester .

    Rochester, Minnesota

  • Oregon Health and Science University SC

    Portland, Oregon

  • Lehigh Valley Health Network SC

    Allentown, Pennsylvania

  • Andrew and Patel Associates

    Camp Hill, Pennsylvania

  • Mays Cancer Ctr Uthsa Mdacc SC-5

    San Antonio, Texas

  • University of Utah / Huntsman Cancer Institute Oncology

    Salt Lake City, Utah

  • Novartis Investigative Site

    La Rioja, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Buenos Aires, Buenos Aires F.D., Argentina

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Clermont-Ferrand, France

  • Novartis Investigative Site

    La Tronche, France

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Pierre-Bénite, France

  • Novartis Investigative Site

    Rennes, France

  • Novartis Investigative Site

    Strasbourg, France

  • Novartis Investigative Site

    Marseille, Bouches Du Rhone, France

  • Novartis Investigative Site

    Dijon, Cote D Or, France

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Cologne, Germany

  • Novartis Investigative Site

    Frankfurt, Germany

  • Novartis Investigative Site

    Göttingen, Germany

  • Novartis Investigative Site

    Halle, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Hanover, Germany

  • Novartis Investigative Site

    Homburg, Germany

  • Novartis Investigative Site

    München, Germany

  • Novartis Investigative Site

    Nuremberg, Germany

  • Novartis Investigative Site

    Ravensburg, Germany

  • Novartis Investigative Site

    Tübingen, Germany

Showing 40 of 95 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.